METHODS article

Front. Pharmacol.

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1522650

Effectiveness of a structured pharmaceutical review of pharmacotherapeutic plans to reduce drug-related problems in nursing homes: a study protocol of a pragmatic quasi-experimental trial

Provisionally accepted
Cecília  Campabadal PratsCecília Campabadal Prats1*Enric  AragonèsEnric Aragonès2Marta  RomeuMarta Romeu3Clara  Salom-GarriguesClara Salom-Garrigues1Ferran  BejaranoFerran Bejarano1Francisco  Martín LujánFrancisco Martín Luján2Laura  CanadellLaura Canadell1
  • 1Atenció Primària Camp de Tarragona; Institut Català de la Salut. Hospital Joan XXIII, Tarragona, Spain
  • 2Unit of research, Atenció Primària Camp de Tarragona; Institut Català de la Salut., Tarragona, Spain
  • 3Unit of Pharmacology, Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, Spain., Tarragona, Spain

The final, formatted version of the article will be published soon.

Background: Patients living in nursing homes have increased aging, comorbidity, spending on health resources and mortality. High drug use is associated with an increased risk of falls, disability, and death. It is estimated that 20-50% of inappropriate medications are consumed in the elderly.Objective: This abstract outline the study protocol for evaluating the effectiveness of a pharmaceutical intervention designed to optimize medication use among nursing home residents, with a particular focus on reducing drug-related problems (DRPs) and minimizing polypharmacy.The pharmaceutical intervention led by a primary care pharmacist and based on systematically reviewing the pharmacotherapeutic plans of patients admitted to nursing homes will effectively improve the quality and safety of treatment plans.Methodology: Pre-post, quasi-experimental intervention study with a control group and prospective 3-month follow-up of a cohort of patients in nursing homes. The intervention consists of a clinical review of the pharmacotherapeutic plan carried out by the pharmacist and subsequently agreed upon in the pharmacotherapeutic advisory committee.The study variables will be evaluated at baseline and 3 months postintervention. The outcome variables are drug-related problems and polymedication.Statistical analysis: Percentage change will be measured before and after the intervention. Descriptive statistics will be performed for quantitative variables such as qualitative and comparison of means and proportions.Expected results: Decreasing 10% DRPs in terms of number of DRPs per patient as well as the proportion of patients experiencing DRPs. Reducing 10 % polymedication in terms of the number of drugs per patient as well as the number of polymedicated patients.Applicability and Relevance: This study will expand the collaboration between the pharmacy and primary care physicians, promoting the continuum of care, strengthening the safety culture, and improving prescribing habits.

Keywords: Trial registration: ClinicalTrials.gov: NCT05944328, Registered Nursing homes, Polypharmacy, adverse drug event, pharmaceutical care, Drug related problems (DRP)

Received: 04 Nov 2024; Accepted: 23 Jun 2025.

Copyright: © 2025 Campabadal Prats, Aragonès, Romeu, Salom-Garrigues, Bejarano, Martín Luján and Canadell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Cecília Campabadal Prats, Atenció Primària Camp de Tarragona; Institut Català de la Salut. Hospital Joan XXIII, Tarragona, Spain

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.